Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Asthma: where beyond steroids?

C P Bertrand1

  • 1Institut de Recherche Jouveinal/Parke Davis, Fresnes, France. claude.bertrand@wl.com

Current Opinion in Chemical Biology
|August 26, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma.

The European respiratory journal·2011
Same author

Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice.

The European respiratory journal·2006
Same author

Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2005
Same author

Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis.

Allergy·2002
Same author

Rapid up-regulation of CXC chemokines in the airways after Ag-specific CD4+ T cell activation.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

CCR3 blockade as a new therapy for asthma.

Expert opinion on investigational drugs·2000
Same journal

Function through shape: An overview of DNA G-quadruplexes in transcriptional regulation.

Current opinion in chemical biology·2026
Same journal

Advances in tools and technologies for multiplexed bioluminescence imaging.

Current opinion in chemical biology·2026
Same journal

High-resolution molecular mapping by expansion-coupled label-free and multimodal imaging.

Current opinion in chemical biology·2026
Same journal

Recent advances in glycoconjugate-based therapeutics.

Current opinion in chemical biology·2026
Same journal

Towards better red emitters for bioimaging: Innovations in rhodamine and cyanine chemistry.

Current opinion in chemical biology·2026
Same journal

Chemigenetic fluorescent biosensors in biological imaging - New trends and advances.

Current opinion in chemical biology·2026
See all related articles

Asthma prevalence is rising, prompting new drug development. Emerging therapies focus on inhibiting inflammation, offering potentially safer alternatives to current symptomatic treatments.

Area of Science:

  • Pulmonology and Respiratory Medicine
  • Pharmacology and Drug Discovery

Background:

  • Increasing global prevalence of asthma necessitates novel therapeutic strategies.
  • Current asthma management relies on bronchodilators and anti-inflammatory drugs, which offer symptomatic relief but can cause side effects.
  • Existing treatments are insufficient for a significant patient subset, highlighting the need for advanced interventions.

Purpose of the Study:

  • To review the landscape of novel pharmacotherapies under development for asthma.
  • To evaluate the potential of new anti-inflammatory agents in asthma treatment.
  • To assess the safety and efficacy profiles of emerging asthma medications compared to current standards.

Main Methods:

  • Literature review of ongoing clinical trials and preclinical research in asthma pharmacotherapy.

Related Experiment Videos

  • Analysis of drug development pipelines targeting key inflammatory pathways in asthma.
  • Comparative assessment of novel agents versus established asthma medications.

    • Main Results:

    • Multiple novel drug candidates targeting inflammatory pathways are in development for asthma.
    • These new therapies aim to provide more effective and safer asthma management.
    • Many emerging treatments demonstrate improved safety profiles compared to traditional corticosteroid therapies.

    Conclusions:

    • The pipeline for asthma pharmacotherapy is robust, with a focus on targeted anti-inflammatory mechanisms.
    • New therapeutic options hold promise for improved asthma control and reduced treatment-related adverse events.
    • Further research and clinical trials are crucial to validate the efficacy and safety of these innovative asthma treatments.